Literature DB >> 1767833

Contribution of adrenergic mechanisms to glucose counterregulation in humans.

P De Feo1, G Perriello, E Torlone, C Fanelli, M M Ventura, F Santeusanio, P Brunetti, J E Gerich, G B Bolli.   

Abstract

To assess the role of adrenergic mechanisms during prolonged hypoglycemia, eight normal subjects were studied on six occasions. In study 1, insulin was infused subcutaneously (15 mU.m-2.min-1 for 12 h), and plasma glucose concentration (PG) decreased from 89 +/- 2 to 50 +/- 1 mg/dl. In study 2 (insulin as in study 1 + propranolol and phentolamine + variable glucose to maintain PG as in study 1), the rate of hepatic glucose production (HGO, [3-3H]glucose) was approximately 30% lower after 1.5 h, and the rate of peripheral glucose utilization (GU) was approximately 15% greater after 5 h. To quantitate the effects of adrenergic mechanisms on glucose counterregulation, in a control study (study 3), glucoregulatory hormone secretion was blocked, and the hormones were reinfused to reproduce study 1. When alpha- and beta-blockade plus variable glucose were superimposed to study 3 (study 4), HGO was approximately 25% lower (after 2 h), and GU was approximately 10% greater (after 6 h) vs. study 3. When glucose was not infused to match PG of study 3 (study 5), severe hypoglycemia developed (PG at 7 h 36 +/- 2 vs. 62 +/- 3 mg/dl). Finally, when glucose was not infused during alpha- and beta-blockade of study 2 (study 6), PG was 49 +/- 3 mg/dl at 7 h vs. 65 +/- 3 mg/dl of the control study (study 1), despite greater secretion of glucagon, growth hormone, and cortisol. It is concluded that adrenergic mechanisms play a key counterregulatory role, even in the presence of appropriate responses of glucagon and that greater increases in glucagon (and other counterregulatory hormones) cannot compensate fully for absent contribution of adrenergic mechanisms to counterregulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1767833     DOI: 10.1152/ajpendo.1991.261.6.E725

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice.

Authors:  Rana I Sharara-Chami; Yingjiang Zhou; Steven Ebert; Karel Pacak; Umut Ozcan; Joseph A Majzoub
Journal:  Int J Biochem Cell Biol       Date:  2012-03-03       Impact factor: 5.085

2.  Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.

Authors:  C G Fanelli; P De Feo; F Porcellati; G Perriello; E Torlone; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

3.  Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes.

Authors:  X Fan; Y Ding; S Brown; L Zhou; M Shaw; M C Vella; H Cheng; E C McNay; R S Sherwin; R J McCrimmon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-08       Impact factor: 3.619

4.  Enhanced neuroendocrine response to insulin tolerance test performed under increased ambient temperature.

Authors:  D Jezová; R Kvetnanský; K Nazar; M Vigas
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

5.  Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans.

Authors:  C Fanelli; S Pampanelli; L Epifano; A M Rambotti; M Ciofetta; F Modarelli; A Di Vincenzo; B Annibale; M Lepore; C Lalli
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

6.  Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.

Authors:  Ulrich Werner; Norbert Tennagels; Carmine G Fanelli; Geremia B Bolli
Journal:  Diabetes Obes Metab       Date:  2020-10-19       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.